German specialty chemicals company Evonik reported a strong second quarter on August 4, 2026, with adjusted EBITDA rising 24% year on year to EUR 630 million. The company also raised its full-year 2026 guidance, expecting adjusted EBITDA between EUR 2.0 billion and EUR 2.2 billion.
The results stand out as one of the stronger performances in the European chemical sector. However, Evonik stressed that the improvement does not reflect a full industry recovery, but rather a combination of global supply chain disruptions, shifting competitive dynamics and internal cost optimization efforts.
Headquartered in Essen, Germany, Evonik operates across specialty chemicals, high-performance materials, additives, animal nutrition and industrial chemical segments. In the second quarter, sales increased 11% year on year to EUR 3.893 billion, supported by both higher volumes and improved pricing.
The company noted that one of the key drivers behind the stronger performance was increased uncertainty in global logistics, partly triggered by geopolitical tensions in the Middle East. These disruptions affected raw material flows and transportation conditions for some Asian competitors, tightening supply in selected markets.
As a result, pricing conditions improved in several product areas, while competitive pressure eased temporarily in certain regions.
The Advanced Technologies segment delivered particularly strong results. Sales rose 9% to EUR 1.647 billion, while adjusted EBITDA increased 25% to EUR 333 million. Evonik highlighted that high-performance polymers, crosslinkers and animal nutrition products benefited from tighter supply conditions and improved pricing.
In animal nutrition, methionine prices recovered due to supply-related market adjustments. In specialty materials, logistics constraints affecting some Asian suppliers contributed to a more favorable competitive environment for European producers.
Despite the strong quarterly performance, management remained cautious about the broader outlook. CEO Christian Kullmann described the current environment as a temporary improvement that eases short-term pressure but does not resolve the structural challenges facing the chemical industry.
These challenges include persistent global overcapacity, continued capacity expansion in China, structurally higher production costs in Europe and a slower-than-expected recovery in end-market demand.
Evonik continues to implement its “Evonik Tailor Made” efficiency program, which includes significant workforce reductions and organizational restructuring over multiple phases through 2029. The strategy reflects a long-term focus on cost reduction, operational efficiency and portfolio concentration in higher-margin specialty businesses.
Across the European chemical industry, similar restructuring trends are visible, with companies such as BASF, Covestro and Wacker Chemie also adjusting capacity, reducing costs and reshaping portfolios in response to prolonged market weakness.
Evonik’s results demonstrate that companies with strong technological capabilities and differentiated product portfolios can still achieve earnings resilience during periods of supply chain disruption and market volatility.
However, a key question remains whether these gains will persist once global logistics normalize and supply constraints in Asia ease.
If competitive pressure returns and supply conditions stabilize, some of the current pricing benefits may fade. Long-term performance will therefore depend more on structural improvements than on temporary market conditions.
Overall, Evonik’s second-quarter results highlight a complex industry environment in which profitability is recovering, but a full recovery of the chemical sector still depends on stronger demand and a more balanced supply-demand structure.
